MedTrace Logo

Germline Testing for Predisposition to Myeloid Malignancies

NCT07112287 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2026-04-24

No results posted yet for this study

Summary

The goal of this research study is to evaluate the feasibility of germline genetic testing using the investigational MyeloGen Gene Panel in adult participants diagnosed with myeloid malignancies.

Conditions

  • Myeloid Malignancy
  • Genetic Predisposition to Disease
  • Myeloid Hematological Malignancies

Interventions

DEVICE

MyeloGen Gene Panel

The MyeloGen Gene Panel is investigational Germline genetic testing using skin fibroblasts.

Sponsors & Collaborators

  • Christopher Reilly

    lead OTHER

  • Broad Institute of MIT and Harvard

    collaborator OTHER

Principal Investigators

  • Christopher R Reilly, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-10
Primary Completion
2030-04-01
Completion
2033-04-01
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07112287 on ClinicalTrials.gov